| Code | CSB-RA004929MB14HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to TNB-738, targeting CD38, a type II transmembrane glycoprotein expressed on various immune cells including plasma cells, activated T cells, and natural killer cells. CD38 functions as both an ectoenzyme with NADase and ADP-ribosyl cyclase activities and as a receptor involved in cell adhesion and signal transduction. This multifunctional protein plays critical roles in calcium signaling, immune regulation, and cellular metabolism. CD38 is highly expressed on malignant plasma cells in multiple myeloma and exhibits elevated expression in various hematological malignancies and certain solid tumors, making it an important therapeutic target in oncology research.
TNB-738 represents an investigational anti-CD38 antibody designed for therapeutic development in hematological cancers. This biosimilar provides researchers with a valuable tool for studying CD38-mediated mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis induction. The antibody supports investigations into immune modulation, tumor microenvironment interactions, and combination therapy strategies in cancer research models.
There are currently no reviews for this product.